Date: 2016-03-22
Type of information: IPO
Company: Corvus Pharmaceuticals (USA - CA)
Investors:
Amount:
Funding type: IPO
Planned used:
Others: * On March 22, 2016, Corvus Pharmaceuticals, a clinical stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology therapies, announced the pricing of its initial public offering of 4,700,000 shares of its common stock at an initial public offering price of $15.00 per share. In addition, the underwriters have a 30-day option to purchase up to an additional 705,000 shares of common stock at the initial public offering price, before underwriting discounts and commissions. The shares are expected to begin trading on The NASDAQ Global Market on March 23, 2016 under the ticker symbol "CRVS." The offering is expected to close on March 29, 2016, subject to the satisfaction of customary closing conditions. Credit Suisse Securities (USA) and Cowen and Company are acting as joint book-running managers for the offering. Guggenheim Securities is serving as lead manager, and Cantor Fitzgerald & Co. and BTIG are serving as co-managers for the offering.
Therapeutic area: Cancer - Oncology
